NT-proBNP blood levels showed strong ability to detect cardiovascular autonomic dysfunction in Parkinson's disease patients, with an AUC of 0.917.
AUC = 0.917NT-proBNP's accuracy in detecting dysautonomia in Parkinson's patients, where 1.0 represents perfect discrimination
What the researchers found
NT-proBNP levels were significantly elevated in Parkinson's disease patients with neurogenic orthostatic hypotension (adjusted P = 0.001) and in those with pathologically absent overshoot during the Valsalva Maneuver (adjusted P = 0.001). The peptide marker also correlated significantly with changes in systolic and diastolic blood pressure during the Head-up Tilt Test (P = 0.011 and P = 0.027, respectively) and with the blood pressure response in Valsalva phase III (P = 0.024).
ROC curve analysis revealed that NT-proBNP had high discriminatory power for detecting dysautonomia in Parkinson's patients, achieving an area under the curve of 0.917 (P < 0.0001). NT-proBNP levels also correlated with patients' self-reported cardiovascular symptoms.
Why it matters
Cardiovascular autonomic dysfunction is common in Parkinson's disease but currently requires specialized, time-consuming autonomic function testing to detect. If NT-proBNP — a simple, widely available blood test — can reliably flag this dysfunction, it could enable earlier identification of at-risk patients and potentially guide treatment decisions for managing orthostatic hypotension and related symptoms.
How the study worked
The researchers enrolled 31 consecutive Parkinson's disease patients and measured their NT-proBNP blood levels. Each patient underwent a battery of cardiovascular autonomic function tests, including the Head-up Tilt Test for orthostatic blood pressure changes, the Valsalva Maneuver for baroreceptor function, the Hand Grip test, and the Deep Breathing test for heart rate variability. They used ROC curve analysis to assess how well NT-proBNP could distinguish patients with dysautonomia, and multivariable linear regression to identify independent associations.
What this study cannot tell us
The study included only 31 patients, which is a small sample size that limits the generalizability of the findings. As a single-center study, the results need validation in larger, more diverse populations. The cross-sectional design means it cannot establish whether elevated NT-proBNP precedes dysautonomia or simply accompanies it. Additionally, patients with known heart failure were likely excluded, so the marker's specificity in patients with concurrent cardiac disease remains unclear.
How to read the evidence
This is a small cross-sectional clinical study with 31 patients at a single center. While the statistical results are strong and the methodology is sound, the small sample size and lack of external validation limit the evidence strength. It represents promising preliminary evidence that warrants larger confirmatory studies.
When this study was published
Published in 2025, this is a very recent study representing the current frontier of research into peptide-based biomarkers for Parkinson's disease autonomic dysfunction.
The bigger picture
Parkinson's disease research increasingly recognizes the non-motor burden of the disease, particularly cardiovascular autonomic failure which contributes to falls, syncope, and reduced quality of life. This study adds NT-proBNP to the emerging toolkit of blood-based biomarkers for non-motor Parkinson's features, bridging cardiology and neurology in a way that could simplify clinical screening for a condition that often goes underdiagnosed.
Questions still open
- Could NT-proBNP serve as an early warning marker for autonomic decline before symptoms become clinically apparent in Parkinson's patients?
- What specific NT-proBNP threshold values would optimize sensitivity and specificity for clinical screening of dysautonomia?
- Does NT-proBNP track with disease progression, and could it be used to monitor autonomic function over time?
Common questions
What is NT-proBNP and why is it relevant to Parkinson's disease?
What is dysautonomia and how does it affect Parkinson's patients?
Read the original research
B-type natriuretic peptide in Parkinson's disease: a novel biomarker of dysautonomia.
Parkinsonism & related disorders, 141, 108079
Citation
Contaldi, Elena; Corradi, Marta; Percetti, Marco; Pilleri, Manuela; Calandrella, Daniela; Isaias, Ioannis U; Pezzoli, Gianni; Del Sorbo, Francesca. (2025). B-type natriuretic peptide in Parkinson's disease: a novel biomarker of dysautonomia.. Parkinsonism & related disorders, 141, 108079. https://doi.org/10.1016/j.parkreldis.2025.108079